2024-03-29T12:56:13Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/142342023-10-09T07:55:46Zcom_20.500.12105_2060com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2061
00925njm 22002777a 4500
dc
GarcĂa de la Sota, Patricia
author
Lorente, Elena
author
Notario, Laura
author
Mir-Gerrero, Carmen
author
Zaragoza, Oscar
author
Lopez, Daniel
author
2021-09-07
Human respiratory syncytial virus (HRSV) is the most common cause of severe respiratory infections in infants and young children, often leading to hospitalization. In addition, this virus poses a serious health risk in immunocompromised individuals and the elderly. HRSV is also a major nosocomial hazard in healthcare service units for patients of all ages. Therefore, the development of antiviral treatments against HRSV is a global health priority. In this study, mitoxantrone, a synthetic anthraquinone with previously reported in vitro antiprotozoal and antiviral activities, inhibits HRSV replication in vitro, but not in vivo in a mice model. These results have implications for preclinical studies of some drug candidates.
Biomedicines. 2021;9(9):1176.
2227-9059
http://hdl.handle.net/20.500.12105/14234
34572362
10.3390/biomedicines9091176
Biomedicines
HRSV
Antivirals
Bioluminescence
Drugs
Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus